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Abstract 
 
Background and Purpose: Glabridin is a major flavonoid in Glycyrrhiza glabra (licorice) root, a 
traditional Asian medicine. Glabridin is reported to have anti-atherogenic, anti-inflammatory and anti-
nephritic properties; however its effects on vascular tone remain unexplored.  
Experimental approach: We examined the effect of glabridin on rat main mesenteric artery using 
isometric myography and also ELISA to measure cGMP levels.  
Key results: Glabridin (30M) relaxed arteries pre-constricted with the thromboxane A2 analog 
U46619 (0.2M) by ~60% in an endothelium-independent manner. Relaxation to 30M glabridin was 
abolished by the guanylate cyclase inhibitor 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one (1M) 
and by the BKCa channel blocker tetraethyammonium (1mM) but was unaffected by the estrogen 
receptor antagonist ICI182780. The concentration-response curve to glabridin (0.1 to 30M) was 
downshifted by the KATP channel blocker glibenclamide (10μM), the KV channel blocker 4-
minopyridine (300M), and the KIR blocker BaCl2 (30 M). In U46619-contracted arteries partially 
relaxed by 0.1 M sodium nitroprusside, application of 10 and 30nM glabridin caused additional 
vasorelaxation. Glabridin (30M) approximately doubled tissue [cyclic GMP]. Application of the 
phosphodiesterase inhibitor isobutylmethylxanthine caused a much larger rise in [cyclic GMP], and 
glabridin failed to cause vasorelaxation or a further rise in [cGMP] when co-applied with IBMX.  
Conclusions and implications: Vasorelaxation to glabridin is dependent on the opening of K
+
 
channels, particularly BKCa, probably caused by a rise in cellular [cyclic GMP] owing to 
phosphodiesterase inhibition. In the presence of sodium nitroprusside an effect of glabridin is 
observed at nM concentrations, similar those measured in plasma following human ingestion of 
licorice flavonoid oil.   
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1. Introduction 
The isoflavone glabridin is an important constituent of licorice root (Glycyrrhiza glabra), from which 
it was first isolated in 1976 [1]. Preparations containing Glycyrrhiza glabra have been used by Indian 
and Chinese medicine for centuries as a treatment for many diseases, including ulcers, bronchitis and 
bacterial infections, and glabridin has anti-oxidant, anti-inflammatory and skin-whitening properties, 
providing a rationale for its inclusion in many cosmetic preparations. Moreover, Glavonoid®, a 
standardised polyphenol extract of licorice root containing 3% glabridin, is being marketed as a food 
supplement and anti-obesity agent, and is added to yoghurt and fruit juices in many Western 
countries.  
 
As described in a recent review by Simmler and colleagues [2], a burgeoning literature comprising 
studies in vitro and in animals in vivo has shown that glabridin has anti-inflammatory, anti-
atherogenic, estrogenic, neuroprotective, and anti-osteoporetic actions. It is however unclear to what 
extent these effects contribute to the putative beneficial actions of licorice-derived preparations 
because most studies have employed micromolar concentrations of glabridin, whereas its likely 
plasma concentration range in humans following ingestion of licorice-derived products is likely to be 
in the low nanomolar range [2]. An exception to this, however, is the glabridin-induced activation of 
estrogen receptors in vascular smooth muscle, which has been observed to occur at concentrations as 
low as 10nM [3].  
 
In view of the widespread and long-standing use of preparations containing Glycyrrhiza glabra and 
the increasing use of glabridin-enriched extracts as food supplements and ingredients, it is noteworthy 
that very little is known about its acute effects on the vasculature. Moreover, Tominaga et al. (2009) 
have demonstrated that ingestion of glabridin for 8 weeks significantly reduced BMI and visceral fat 
in human volunteers [4], implying that glabridin might be useful as a treatment for obesity. 
Considering that obesity is very common in those with hypertension and coronary heart disease, it 
seems likely that the ingestion of glabridin will increase in such patients, in which case it is important 
that potential effects of this agent on the cardiovascular system be understood. We therefore examined 
the effect of glabridin in rat main mesenteric artery using a small vessel isometric myograph, and 
report here for the first time that glabridin acts as a cGMP-dependent vasodilator.  
 
2. Methods 
2.1 Animal welfare and ethical statement 
This study conforms with the Guide for the Care and Use of Laboratory Animals published by the US 
National Institutes of Health (NIH Publication No. 85–23, revised 1996) and is in accordance with 
UK Animals (Scientific Procedures) Act, 1986, Amendment Regulations (SI 2012/3039). Male Wistar 
rats (200–300g; 6–8 weeks old) were killed by lethal injection (i.p.) of sodium thiopental. 
 
2.2 Mounting of mesenteric arteries and measurement of tension development  
Intestines were excised and the main mesenteric artery and its primary branches were removed, placed 
in physiological salt solution (PSS), containing in mM: NaCl 118; NaHCO3 24; KCl 4; CaCl2 1.8; 
MgSO4 1; NaH2PO4 0.43; and glucose 5.56, and the main mesenteric artery was freed of surrounding 
adipose tissue, cut into rings and mounted on a conventional small vessel wire myograph (Danish 
Myo Technology, Aarhus, Denmark). Tension was recorded at a frequency of 1Hz. Mesenteric artery 
rings were stretched to give a basal tension of 2-3 mN, and were equilibrated with three brief 
exposures to PSS containing 80mmol/L KCl (80KPSS; isotonic replacement of NaCl by KCl). 0.2M 
U46619 was then applied to give a near maximal contraction, and endothelial integrity was confirmed 
by recording vasorelaxation to 10M carbachol. Following washout, arteries were again constricted, 
with either 0.2M U46619 or 10 M norepinephrine (NE). When the tension had reached a 
maximum, the vasorelaxing effect of glabridin was recorded as described in the Results. Where 
appropriate, the endothelium was removed by rubbing the vascular lumen with a human hair, and its 
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functional absence was confirmed by the absence of carbachol-induced relaxation. All drugs used in 
these studies were sourced from Sigma-Aldrich, UK). 
 
In order to study the concentration-dependency of glabridin-induced vasorelaxation, the contraction to 
U46619 (or NE, when the effect of glibenclamide was being studied) was allowed to reach its 
maximum, and then ascending concentrations of glabridin, (0.1 - 30M), were applied cumulatively 
at 15 minute intervals, with the effect of glabridin being recorded at the end of each interval. Because 
the contractions to U46619 and NE demonstrated some intrinsic rundown, each arterial ring in which 
glabridin was studied was paired with an arterial segment from the same animal in which the 
amplitude of the contraction to U46619 or NE was recorded in the absence of glabridin at the same 
times at which contraction was measured in the presence of glabridin (i.e. a time control). The percent 
relaxation caused by glabridin was then calculated as 100 x ((1-A)-(1-B))/(1-A), where A was the 
percent relaxation recorded at a given time in the time control segment and B was the percent 
relaxation observed at the same time in the paired segment treated with glabridin. 
 
2.3 cyclic GMP measurements 
Intracellular cyclic GMP (cGMP) in rat mesenteric arteries was measured as previously described [5] 
with minor modifications. Endothelium-intact arterial segments [approx. 5 mg each (wet weight)] 
were equilibrated in PSS for 30 minutes at 37
o
C under continuous carbogen bubbling and were then 
exposed to U-46199 (200nM; 10 minutes), glabridin (30µM; 20 minutes), U46199 (200nM) followed 
by glabridin (30µM; 20 minutes), IBMX (200µM; 30 minutes) and IBMX (200µM; 10 minutes) 
followed by glabridin (30µM; 20 minutes). DMSO (3 µl; 10 minutes) was added as a vehicle control 
to a further group of tissues. Tissues were snap frozen in liquid nitrogen immediately after treatment. 
The frozen tissues were pulverized in a pre-chilled (with liquid nitrogen) pulverizer. The tissue pellet 
was suspended in chilled 5% trichloro acetic acid (200µl) and vortexed vigorously and then 
centrifuged at 5000g for 10 minutes at 8
o
C. Supernatant thus obtained was extracted five times with 
water-saturated diethyl ether and was then used for cGMP assay, using an ELISA kit (Cayman 
Chemical Company, Ann Arbor, MI, USA), following the manufacturer’s instructions. Measurements 
were made in 3 aliquots from each tissue, and resulting values were averaged to produce each data 
point used in subsequent calculations. Tissue pellets obtained after centrifugation were dissolved in 
0.5N NaOH for protein estimation by the BCA method and the concentration of cGMP was expressed 
as picomoles/mg protein.   
 
2.4 Data analysis and statistical procedures  
Results were generally analyzed using Student’s unpaired or paired t-test, as appropriate, with p<0.05 
taken to indicate statistical significance. Results are shown as mean ± SEM. The effects of antagonists 
on the galbridin concentration-response relationship shown in Figure 4 were analysed using repeated 
measures ANOVA with a Bonferroni post hoc test. GraphPad Prism version 7 was used for statistical 
analysis and preparation of figures.  
 
 
3. Results 
Initial experiments revealed that 30M glabridin caused a rapid and robust relaxation of mesenteric 
arteries constricted with 0.2mM U46619. Figure 1A illustrates an example of the vasorelaxing effect 
of 30 M glabridin in endothelium-intact mesenteric arteries (note the endothelium-dependent 
relaxation of the U46619 contracture to 10M acetylcholine; ACh). Similar responses to glabridin 
were observed in endothelium-intact mesenteric arteries which had been pre-treated with 300M L-
NAME and 10 M indomethacin to prevent the synthesis of nitric oxide (NO) and prostacyclin (PGI2) 
respectively (Figure 1B) and also in the absence of endothelium (Figure 1C). These data indicated that 
the endothelium played no role in mediating glabridin-induced relaxation. 
Figure 2 presents evidence that relaxation induced by 30M glabridin was strongly dependent on the 
opening of large-conductance Ca
2+
 activated K
+
 (BKCa) channels. As shown in Figure 2A, glabridin 
caused no relaxation of U46619-constricted arteries in PSS in which the [K
+
] had been raised to 15 
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mM in order suppress any hyperpolarization (and resulting relaxation) associated with K
+
 channel 
opening. Glabridin-induced relaxation was also strongly inhibited in the presence of the BKCa channel 
blocker tetraethylammonium (TEA; 1mM) (Figure 2B). Conversely, neither the KV channel 
antagonist 4-aminopyridine (4-AP; 300 M) nor the KIR channel blocker BaCl2 (30M) had any 
significant effect on the response to glabridin (Figures 2C and D, respectively). The KATP channel 
blocker glibenclamide was used in order to determine whether these channels were involved in 
relaxation induced by 30M glabridin. Because glibenclamide blocks contractions induced by 
U46619 [6], NE (10M) was used to elicit pre-constriction in these experiments. As shown in Figure 
2E and 2F, glabridin-induced relaxation of the norepinephrine contraction, which was similar to that 
observed when U46619 was used to cause preconstruction, was unaffected by glibenclamide. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Lack of involvement of the endothelium in glabridin-induced vasorelaxation. 
Representative traces illustrating the relaxation by 30M glabridin of mesenteric arteries 
preconstricted with 0.2 M U46619. A) endothelium-intact artery, B) endothelium-intact artery 
pretreated with 300M L-NAME and 10M indomethacin, C) endothelium-denuded artery, 
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Figure 2: Effects of 15mM K
+
 and K
+
 channel antagonists on glabridin-induced vasorelaxation. 
Representative traces illustrating the effect of 30 M glabridin on the U46619-induced contraction in 
the presence of (A) PSS containing 15 mM K
+
, (B) 1 mM TEA, (C) 300 M 4-AP, and (D) 30 M 
Ba
2+
. E) Representative traces showing the effect of 30M glabridin on the norepinephrine -induced 
contraction in the absence (left) and presence (right) of 10M glibenclamide (F).  
 
Figure 3 presents the mean effects of endothelial denudation, the combination of L-NAME and 
indomethacin, 15 mM K
+
 PSS, and the K
+
 channel blockers on the vasorelaxation measured 10 
minutes after the application of 30 M glabridin. 
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Figure 3: Mean effect of 30M glabridin under control conditions and following interventions 
designed to block endothelium –dependent or K+ channel- mediated vasorelaxation. Mean ± 
SEM percent relaxation induced by 30 M glabridin under the various conditions illustrated by the 
traces in Figures 1 and 2. Asterisks indicate that the effect of glabridin under a particular condition 
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was significantly (p < 0.05) different than that recorded under control conditions (i.e. endothelium-
intact mesenteric arteries pre-constricted with 0.2 M U46619). Each bar represents the results of 6-
11 experiments. 
 
Although the results shown in Figures 2 and 3 indicate that BKCa channels play an overriding role in 
the response to 30 M glabridin, they do not rule out the possibility that other K+ channels might be 
involved in the vasorelaxation caused by lower glabridin concentrations. We therefore examined the 
concentration-dependency of glabridin-mediated vasorelaxation in the presence and absence of the K
+
 
channel blockers TEA, 4-AP, Ba
2+
 and glibenclamide. We similarly examined the effect of 300M L-
NAME and 10M indomethacin on the glabridin concentration-response relationship.  
As shown in Figure 4, whereas the combination of L-NAME and indomethacin had no significant 
effect on the glabridin concentration-response curve, 4-AP, Ba
2+
 (Figure 4A) and glibenclamide 
(Figure 4B) appeared to generally suppress vasorelaxation at lower glabridin concentrations. This 
attenuation of the response to glabridin was not significant for individual concentrations of any of 
these three blockers with the exception of the effect of glibenclamide on the response to 10M 
glabridin. However the effect on the entire concentration-response curve for each of these blockers, as 
assessed using repeated measures ANOVA, was highly significant. TEA, which had almost abolished 
the response to 30 M glabridin, had a similar effect over the entire range of concentrations tested 
(Figure 4A).  
Although ≤ 1M glabridin often appeared to cause a concentration-dependent vasorelaxation, this 
effect was not statistically significant. This may have been because its effect at these low 
concentrations was slow and therefore difficult to unambiguously distinguish from the gradual 
intrinsic decay of the U46619 contraction. In order to determine whether the possible effect of 1M 
glabridin on tension was real, we therefore used a pre-treatment protocol, as illustrated in Figure 5. In 
these experiments,  
 
Figure 4: Effects of blockers on the 
concentration-response curve for glabridin 
vasorelaxation. 
 
(A) Mean ± SEM percent relaxation of the 
contraction to 0.2mM U46619 induced by 0.1 
- 30 M glabridin under control conditions 
and in the presence of 300M L-NAME and 
10M indomethacin, 1 mM TEA,  300 M 4-
AP, and 30 M Ba2+. (B) Mean ± SEM 
percent relaxation of the contraction to 10M 
NE induced by 0.1 - 30 M glabridin under 
control conditions and in the presence of 
10M glibenclamide. For both panels, * to the 
right of the point at 30M glabridin indicate a 
significant inhibition of the response to 
glabridin over the range of concentrations 
examined, whereas # adjacent to a point on 
the curve indicates a significant effect of the 
blocker at that concentration of glabridin. 
Vasorelaxation was corrected for intrinsic 
time-dependent rundown of the contractile 
response as described in the Methods. Each 
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curve represents the results of 5-8 
experiments. 
 
 
glabridin was applied at the peak of the U46619 contraction. 30 minutes later, U46619 and glabridin 
were washed out of the bath, and 1 M glabridin was immediately re-applied. Following a further 30 
minute incubation in glabridin, U46619 was again applied, and the peak contraction was recorded. As 
shown in Figure 5, the second U46619 contraction was smaller the first. In five similar experiments, 
the amplitude of the U46619 contraction fell by 27.0 ± 6.8% in the presence of glabridin (from 12.7 ± 
1.4 to 9.4 ± 1.4mN, p<0.05 by paired T-test). 
3m
N
10min
U46619 (200nM)
glabridin (1M)
 
Figure 5: Effect of pretreatment with 1M glabridin on the amplitude of the U46619 
contraction. Representative trace illustrating the effect of 60 minute pretreatment with 1 M 
glabridin on the contraction evoked by 0.2 M U46619. 
 
Cyclic nucleotides are known to open BKCa channels present in vascular smooth muscle. As shown in 
Figures 6A and 6E, the guanylate cyclase inhibitor 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one 
(ODQ; 1M) abolished the effect of 30M glabridin. The efficacy of this concentration of ODQ 
against guanylate cyclase was evidenced by its ability to ablate vasorelaxation elicited by the NO 
donor SNP (Figure 6B, E). On the other hand, the protein kinase A antagonist KT-5720 (1M, Figure 
5C) and the estrogen receptor blocker ICI 182780 (10 M; Figure 6D, E) had no effect on the 
relaxation to 30M glabridin. Further evidence that glabridin was not acting via estrogen receptors is 
presented in Figure 6F. Whereas treatment of tissues with the selective estrogen receptor modulator 
raloxifene (10 M) attenuated the contraction induced by depolarization with 80mM KPSS (49.5), 
glabridin (30 M) did not affect the response to high K+ (2.4± 3.3% decrease, n=4, ns vs control, 
p<0.05 vs effect of raloxifene). 
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Figure 6: Effects of ODQ, KT5720 and ICI 182 780 on vasorelaxation of the contraction to 200 
nM U46619 by 30 M glabridin. A) Representative trace showing the effect of glabridin in the 
presence of 1 mM ODQ. B)  Representative traces showing the effect of SNP in the absence (black 
line) and presence (grey line) of 1 M ODQ. Representative traces showing the effect of glabridin in 
the presence of KT5720 (C; 1 M) and ICI 182 780 (D; 10M). E) Average relaxation of the U46619 
contraction by glabridin in the absence of another drug, and in the presence of KT5720, ODQ, and ICI 
182 780). Numbers of experiments used to calculate the results are shown over the bars, and asterisks 
represent a significant difference vs the control relaxation. (F) Representative traces depicting the 
effect on the contraction evoked by 80KPSS of pre-incubation of arteries with 10M raloxifene (top) 
or 30M glabridin (bottom).  
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The results described above were consistent with the possibility that glabridin was causing 
vasorelaxation via a cGMP-dependent activation of K
+
 channels. In this case, it would be predicted 
that glabridin should increase the cellular concentration of cGMP. As illustrated in Figure 7A, a 15 
minute treatment with 30 M glabridin caused a significant increase in the cyclic GMP content of 
segments of mesenteric artery, which was similar in the presence and absence of 200 nM U46619, 
which itself had no effect on the cGMP content. 
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Figure 7: Effects of 30 M glabridin on cGMP levels in rat mesenteric artery segments in the 
presence and absence of U46619. * indicates a significant effect of glabridin on [cGMP] compared 
to the corresponding control. Numbers of experiments (i.e. measurements in individual artery 
segments) used to calculate the results are shown over the bars, and asterisks represent a significant 
difference vs the control relaxation. 
 
The two most straightforward possible explanations for the ability of glabridin to raise the cGMP 
content of the arteries were that it was either stimulating guanylate cyclase or inhibiting 
phosphodiesterase (PDE).  In this case, we reasoned that if glabridin was acting as a PDE inhibitor it 
would exert no effects on vascular tone or tissue cGMP if PDE was already maximally inhibited. 
Conversely, if glabridin was acting by stimulating guanylate cyclise, its effects on vascular tone and 
[cGMP] should persist (and might even be potentiated) if it was applied when PDE was already 
blocked. We therefore examined the effects of glabridin in the presence of a high concentration (200 
M) of the non-selective cGMP PDE inhibitor isobutylmethylxanthine (IBMX).  
Figure 8A shows that treatment with 100 M IBMX was enough to virtually abolish the U46619 
contraction to 200 nM U46619. However, even in the presence of a somewhat higher concentration of 
IBMX (200M), it was possible to evoke a contraction which was of sufficient amplitude to be 
measured accurately if a very high concentration of U46619 (30M) was used (Figure 8B). This 
residual contraction was unaffected by the application of 30 M glabridin (Figure 8B). On the other 
hand, subsequent application of the nitric oxide donor SNP (300nM), which would be expected to 
stimulate guanylate cyclase, caused a marked vasodilation.  These results are summarised in Figure 
8C. Figure 8D llustrates the effect of 200 M IBMX and the combination of 200 M IBMX and 30 
M glabridin on the cGMP content of segments of mesenteric artery. IBMX caused the expected large 
rise in [cGMP], but glabridin exerted no further effect.  
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Figure 8: Effect of IBMX on glabridin-induced responses. A) Representative trace showing the 
effect of IBMX on the contraction induced by 200 nM U46619. B) Trace illustrating the effect of 
sequential addition of 30M glabridin and 100 nM SNP on the contraction evoked by 30M U46619 
in the presence of 200M IBMX. C) Average vasorelaxation elicited  by 30M glabridin when 
applied in the presence of 200 nM U46619  or 200M IBMX and 200nM U46619, and vasorelaxation 
to 300nM SNP when applied in the presence of 200nM U46619  or 200M IBMX and 200nM 
U46619. * indicates a significant block of the response to glabridin or SNP in the presence of IBMX. 
D) Effects of 200 mM IBMX on cGMP levels in rat mesenteric artery segments in the absence and 
presence of 30 M glabridin. * indicates a significant increase in cGMP content compared to control. 
In panels C and D, numbers of experiments (i.e. measurements from individual arterial segments) 
used to calculate the results are shown over the bars. 
 
In light of the possibility that glabridin might be acting as a PDE inhibitor, we reasoned that the 
vasorelaxing effects of low concentrations of glabridin might be potentiated if cGMP levels were first 
elevated by the NO donor sodium nitroprusside (SNP). We therefore applied 100 nM SNP at the peak 
of the U46619 contraction to evoke an immediate relaxation of 30-40%, and then applied 10 and 
30nM glabridin. Tension levels in the presence of glabridin were compared to tension during the same 
period in control tissues in which only SNP was added. Results from 7 tissues treated with glabridin 
were normalized and averaged, and are illustrated in Figure 9A. It is evident that whereas the level of 
tension tended to recover slightly in the presence of SNP only, tension fell in a stepwise manner after 
application of 10 and 30 nM glabridin. Figures 9B and 9C depict individual experiments in which 
glabridin was either applied or not applied after SNP. Figure 9D represents the mean relaxation 
observed when the effects of SNP or SNP + glabridin had stabilized (left), or during the same time 
intervals in arteries to which only SNP had been added (right). Figure 9E shows the mean increase in 
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relaxation between these time periods in the presence and absence of glabridin. Glabridin relaxed the 
arteries significantly at both 10 and 30 nM, whereas no significant time-dependent relaxation was 
observed with SNP alone; 
moreover this difference was significant. These data indicate that glabridin exerts a small but 
measurable effect on mechanisms controlling vascular tone at concentrations which are relevant to the 
use of this drug as a possible therapeutic agent [7]. 
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Figure 9: Glabridin (10 and 30 nM) caused further relaxation of the contraction to 200 nM 
U46619 in the presence of 0.1 M SNP. (A)Arteries were contracted with 200 nM U46619 and then 
0.1 M SNP was applied to cause a partial relaxation. Subsequent application of 10 and then 30 nM 
glabridin caused further relaxation. The trace represents averaged data points from seven individual 
experiments. * indicates a significant fall in the average tension level during the final 120 sec of the 
periods during which 10 and 30 nM glabridin were present, compared to the final 120 sec of the 
period just prior to glabridin application, and # indicates a significant difference between the average 
tension recorded during these intervals in the presence of 10 and 30 nM glabridin. (B)Representative 
trace from one of the seven experiments from which the averaged data in panel A is derived. (C) 
Representative trace of a time control experiment, in which SNP but not glabridin was applied during 
the response to U46619. (D) The white bars represent the mean ± SEM % relaxation observed in the 
presence of SNP alone, and in SNP following the application of 10nM and then 30nM glabridin, 
calculated using the average tension recorded 350-600, 1200-1800 and 2200-2800 after the 
application of SNP, respectively. The black bars represent the % relaxation recorded in five 
experiments over the same time intervals after the application of SNP alone. (F) The white bars show 
the mean ± SEM change in % relaxation induced by 10nM and 30nM glabridin compared to SNP 
alone. The black bars show the mean ± SEM change in % relaxation which occurred during the 
corresponding time intervals when SNP but not glabridin was present. * indicates a significant 
difference between the % relaxation in the presence and absence of 10 and 30 nM glabridin. 
 
4. Discussion and Conclusions 
Glabridin has been shown to have several effects which could be beneficial for the cardiovascular 
system, although the extent to which these contribute to the putative therapeutic actions of licorice 
root is unclear. Notably, in vitro and in vivo studies show that glabridin inhibits low density 
lipoprotein oxidation and atherogenesis [8], possibly by inhibiting NADPH oxidase [9] or by 
increasing the expression of antioxidant enzymes in macrophages [10].  Somjen et al., (2004) also 
showed that 30 nM glabridin caused DNA synthesis and a stimulation of creatine kinase activity in an 
endothelial cell line (ECV-304) and cultured uterine artery smooth muscle cells [3]. Both effects were 
blocked by the estrogen receptor antagonist raloxifene.  Moreover, glabridin has been shown to 
reduce adiposity in obese rodents, an action which may result from an inhibition of mitochondrial 
ATP synthesis with a consequent stimulation of AMP kinase [11]. 
Our observations indicate that glabridin evokes vasorelaxation by opening K
+
 channels, an effect 
which would be predicted to cause vascular smooth muscle cell hyperpolarization, resulting in the 
closure of voltage-gated Ca
2+
 channels and, as a consequence, a fall in [Ca
2+
]. This would explain the 
abolition of the response to glabridin in PSS containing 15 mM K
+
, at which concentration smooth 
muscle hyperpolarization beyond -50 mV should be prevented [12]. The virtual abolition of the 
glabridin-induced relaxation by TEA, which is relatively selective for BKCa channels at the 
concentration we employed (1mM) [13], indicates a predominant role for this type of K
+ 
channel. 
However, relaxation to lower concentrations of glabridin was also attenuated by blockers of voltage-
gated (KV), inwardly rectifying (KIR) and ATP-sensitive (KATP) K
+
 channels, suggesting that the 
opening of these channels was reinforcing BKCa-induced hyperpolarization. 
Relaxation was blocked by the guanylate cyclase inhibitor ODQ, indicating that glabridin-induced 
relaxation was likely occurring via cGMP. This possibility was supported by the finding that glabridin 
caused an approximately two-fold increase in the cGMP content of arterial segments. There is 
abundant evidence that raising VSMC cGMP levels results in the activation of K
+
 channels. A link 
between the activation of the cGMP/G kinase pathway and the opening of BKCa channels has been 
well characterized [14,15], and there is also evidence, albeit less well documented, that this second 
messenger system can activate KV (16, 17], KIR, [17] and KATP [17-19] channels in vascular smooth 
muscle. 
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Glabridin might increase [cGMP] either by promoting its synthesis or by inhibiting its breakdown, 
e.g. by acting as a PDE inhibitor. In the former case, it would be predicted that inhibition of PDE 
would not prevent, or would enhance, glabridin’s actions, whereas in the latter one might expect that 
glabridin would have no effect. We observed that following treatment of mesenteric arteries with 200 
M IBMX, glabridin was no longer able to cause relaxation. Moreover, the combination of glabridin 
and IBMX caused an increase in tissue [cGMP] which was similar to that induced by IBMX alone. 
This concentration of IBMX would be expected to fully block PDE5 [20], the main PDE involved in 
metabolizing cGMP in the vasculature [21]. These data therefore are consistent with the possibility 
that glabridin is acting as a PDE inhibitor. 
A recent comprehensive review of the pharmacodynamics and pharmacokinetics of glabridin [2] has 
highlighted the fact that glabridin’s antioxidant properties, which are thought to be responsible for 
many of its other biological effects, have been observed in studies employing micromolar 
concentrations, whereas its plasma concentrations are likely to be closer to 10 nanomolar. On the 
other hand, concentrations of glabridin in the nanomolar range stimulated estrogen receptors [3], 
leading Simmler et al. to suggest that, of all the documented effects of glabridin, its estrogenic 
properties were most worthy of further study [2]. As stimulation of estrogen receptors has been shown 
to cause acute vascular relaxation via a mechanism which is dependent on cyclic GMP and BKCa 
channels [22-25] we examined whether the vasorelaxation to glabridin was blocked by the estrogen 
receptor antagonist ICI 182 780, and found that it was not.  However the lack of effect of ICI 182780 
did not provide definitive evidence against a role for estrogen receptors, because although this drug 
was observed to block 17-estradiol -induced vasorelaxation in some arteries [19,26], it was reported 
to have no effect on the relaxation to either 17-estradiol or the selective estrogen receptor modulator 
raloxifene in rat superior mesenteric arteries [25]. Chan and colleagues similarly showed that dilation 
by raloxifene of third-order rat mesenteric arteries was insensitive to ICI 182780, and that this effect 
of raloxifene was almost completely suppressed by L-NAME [27]. However, we saw no effect of L-
NAME on the response to glabridin. More importantly, raloxifene was shown by Tsang et al. (2004) 
to relax depolarization-induced contractions in rat cerebral arteries [28], and whereas we similarly 
found that raloxifene markedly attenuated the contraction evoked by 80KPSS in rat mesenteric 
arteries, glabridin had no effect on the high K
+
 contraction. On balance, therefore, the results with ICI 
182780 and raloxifene imply strongly that glabridin was not causing vasorelaxation by stimulating 
estrogen receptors.  
Glabridin concentrations in the plasma following ingestion of licorice root-containing preparations are 
not known. Aoki et al., (2007) estimated steady state plasma glabridin concentrations were between 
0.6 and 2.4 ng/ml (2-7 nM) in healthy human subjects who ingested 1200mg of licorice flavonoid oil 
(LFO; contained ~ 12 mg of glabridin) daily for several weeks, a dose which was apparently tolerated 
with no ill effects [7]. Tominaga et al., 2009 used a similar dose (900mg daily) to show in a 
randomized trial that LFO caused a significant reduction in BMI and visceral fat [4]. Although we did 
not attempt to examine the effect of glabridin applied on its own at concentrations below 0.1M, its 
application at concentrations of 10 and 30 nM caused further vasorelaxation when added in the 
presence of 100nM SNP.  It therefore seems that glabridin is able to exert measurable acute effects on 
vascular tone at plasma concentrations close to those which could occur in individuals ingesting 
glabridin-enriched foods or supplements.   
In conclusion, our results indicate that glabridin induced a vasorelaxation of rat mesenteric arteries 
which was associated with the opening of K
+
 channels and a concomitant rise in tissue cGMP levels. 
Glabridin was not able to cause vasodilation, or a further rise in cGMP, in the presence of the non-
selective PDE inhibitor IBMX, consistent with the possibility that it was acting as a PDE inhibitor. In 
the presence of SNP, a measurable vasorelaxing effect of glabridin was observed at nanomolar 
concentrations, implying that glabridin may be able to influence vascular tone at plasma 
concentrations which might be attained following its consumption, particularly in the presence of 
another drug which has raised cGMP levels. Verification of the relevance of these findings to the use 
of glabridin as a food supplement or and aid to weight loss [4] must, however, await future studies in 
humans. 
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6. Figure legends 
 
Figure 1: Lack of involvement of the endothelium in glabridin-induced 
vasorelaxation.Representative traces illustrating the relaxation by 30M glabridin of mesenteric 
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arteries preconstricted with 0.2 M U46619. A) endothelium-intact artery, B) endothelium-denuded 
artery, C) endothelium-intact artery pretreated with 300M L-NAME and 10M indomethacin. 
 
Figure 2: Effects of 15mM K
+
 and K
+
 channel antagonists on glabridin-induced 
vasorelaxation.Representative traces illustrating the effect of 30 M glabridin on the U46619-
induced contraction in the presence of (A) PSS containing 15 mM K
+
, (B) 1 mM TEA, (C) 300 M 4-
AP, and (D) 30 M Ba2+. E) Representative traces showing the effect of 30M glabridin on the 
norepinephrine -induced contraction in the absence (left) and presence (right) of 10M glibenclamide.  
 
Figure 3: Mean effect of 30M glabridin under control conditions and following interventions 
designed to block endothelium –dependent or K+ channel- mediated vasorelaxation.Mean ± SEM 
percent relaxation induced by 30 M glabridin under the various conditions illustrated by the traces in 
Figures 1 and 2. Asterisks indicate that the effect of glabridin under a particular condition was 
significantly (p < 0.05) different than that recorded under control conditions (i.e. endothelium-intact 
mesenteric arteries preconstricted with 0.2 M U46619). Each bar represents the results of 6-11 
experiments. 
 
Figure 4: Effects of blockers on the concentration-response curve for glabridin vasorelaxation. 
(A) Mean ± SEM percent relaxation of the contraction to 0.2mM U46619 induced by 0.1 - 30 M 
glabridin under control conditions and in the presence of 300M L-NAME and 10M indomethacin, 
1 mM TEA,  300 M 4-AP, and 30 M Ba2+. (B) Mean ± SEM percent relaxation of the contraction 
to 10M NE induced by 0.1 - 30 M glabridin under control conditions and in the presence of 10M 
glibenclamide. For both panels, * to the right of the point at 30M glabridin indicate a significant 
inhibition of the response to glabridin over the range of concentrations examined, whereas # adjacent 
to a point on the curve indicates a significant effect of the blocker at that concentration of glabridin. 
Vasorelaxation was corrected for intrinsic time-dependent rundown of the contractile response as 
described in the Results. Each curve represents the results of 5-8 experiments. 
 
Figure 5: Effect of pretreatment with 1M glabridin on the amplitude of the U46619 
contraction. Representative trace illustrating the effect of 60 minute pretreatment with 1 M 
glabridin on the contraction evoked by 0.2 M U46619. 
 
Figure 6: Effects of ODQ, KT5720 and ICI 182 780 on vasorelaxation of the contraction to 200 
nM U46619 by 30 M glabridin. A) Representative trace showing the effect of glabridin in the 
presence of 1 mM ODQ. B)  Representative traces showing the effect of SNP in the absence (black 
line) and presence (grey line) of 1 M ODQ. Representative traces showing the effect of glabridin in 
the presence of KT5720 (C; 1 M) and ICI 182 780 (D; 10M). E)Average relaxation of the U46619 
contraction by glabridin in the absence of another drug, and in the presence of KT5720, ODQ, and ICI 
182 780). Numbers of experiments used to calculate the results are shown over the bars, and asterisks 
represent a significant difference vs the control relaxation. (F)Representative traces depicting the 
effect on the contraction evoked by 80KPSS of preincubation of arteries with 10M raloxifene (top) 
or 30M glabridin (bottom).  
 
Figure 7: Effects of 30 M glabridin on cGMP levels in rat mesenteric artery segments in the 
presence and absence of U46619. * indicates a significant effect of glabridin on [cGMP] compared 
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to the corresponding control.Numbers of experiments (i.e. measurements in individual artery 
segments) used to calculate the results are shown over the bars, and asterisks represent a significant 
difference vs the control relaxation. 
 
Figure 8: Effect of IBMX on glabridin-induced responses. A) Representative trace showing the 
effect of IBMX on the contraction induced by 200 nM U46619. B) Trace illustrating the effect of 
sequential addition of 30M glabridin and 100 nM SNP on the contraction evoked by 30M U46619 
in the presence of 200M IBMX. C) Average vasorelaxation elicited  by 30M glabridin when 
applied in the presence of 200 nM U46619  or 200M IBMX and 200nM 46619, and vasorelaxation 
to 300nM SNP when applied in the presence of 200nM U46619  or 200M IBMX and 200nM 
U46619. * indicates a significant block of the response to glabridin or SNP in the presence of IBMX. 
D) Effects of 200 mM IBMX on cGMP levels in rat mesenteric artery segments in the absence and 
presence of 30 M glabridin. * indicates a significant increase in cGMP content compared to control. 
In panels C and D, numbers of experiments (i.e. measurements from individual arterial segments) 
used to calculate the results are shown over the bars. 
 
Figure 9: Glabridin (10 and 30 nM) caused further relaxation of the contraction to 200 nM 
U46619 in the presence of 0.1 M SNP. (A) Arteries were contracted with 200 nM U46619 and then 
0.1 M SNP was applied to cause a partial relaxation. Subsequent application of 10 and then 30 nM 
glabridin caused further relaxation. The line represents the average of seven individual experiments. * 
indicates a significant fall in the average tension level during the final 120 sec of the periods during 
which 10 and 30 nM glabridin were present, compared to the final 120 sec of the period just prior to 
glabridin application, and # indicates a significant difference between the average tension recorded 
during these intervals in the presence of 10 and 30 nM glabridin. (B)Representative trace from one of 
the seven experiments from which the mean data in panel A is derived. (C) Representative trace of a 
time control experiment, in which SNP but not glabridin was applied during the response to U46619. 
(D) The white bars represent the mean ± SEM % relaxation observed in the presence of SNP alone, 
and in SNP following the application of 10nM and then 30nM glabridin, calculated using the average 
tension recorded 350-600, 1200-1800 and 2200-2800 after the application of SNP, respectively. The 
black bars represent the % relaxation recorded in five parallel time control experiments over the same 
time intervals after the application of SNP alone. (F) The white bars show the mean ± SEM change in 
% relaxation induced by 10nM and 30nM glabridin compared to SNP alone. The black bars show the 
mean ± SEM change in % relaxation which occurred during the corresponding time intervals when 
SNP but not glabridin was present. * indicates a significant difference between the % relaxation in the 
presence and absence of 10 and 30 nM glabridin. 
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